ASLAN Pharmaceuticals today announced that two abstracts on varlitinib and ASLAN003 have been accepted for presentation at the upcoming 2018 European Society for Medical Oncology (ESMO) Congress in Munich, Germany on 19 – 23 Oct 2018.
For more information, please refer to the English or Chinese press release.